Apellis Pharmaceuticals 3Q Loss/Shr $1.17 >APLS

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90

Apellis Pharmaceuticals Stock Shows Rising Relative Strength

12 Roundtable Picks on the Future of Healthcare

12 Picks to Play the Future of Healthcare, From Our Roundtable Pros

Apellis Pharmaceuticals Cutting 25% of Workforce

Foot Locker, Peloton, AMC, Nvidia, Abercrombie, Apellis, and More Stock Market Movers

Apellis Soars 30% After Identifying Potential Culprit Behind Eye Drug Safety Woes

Foot Locker, Peloton, AMC, Nvidia, Abercrombie, Apellis, and More Stock Market Movers

Apellis Soars 32% After Identifying Potential Culprit Behind Eye Drug Safety Woes

Nvidia, Foot Locker, Peloton, Analog Devices, Apellis, and More Stock Market Movers

Stocks to Watch: Apellis Pharmaceuticals

Apellis Pharmaceuticals Shares Surge 32% on Syfovre Update Following Safety Concerns

Health Care Up on Defensive Rotation -- Health Care Roundup

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin

Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat

Apellis Pharma Shares Drop 15% After Narrower-Than-Expected 2Q Loss

Apellis Pharmaceuticals 2Q Loss/Shr $1.02 >APLS

Apellis Pharmaceuticals Shares Rise 14% After Positive Syfovre Data

Apellis Pharma Down for a Second Day After Inflammation Reports, Shares Fall 25%